Literature DB >> 20609863

The complex clinical picture of side effects to biologicals.

Oliver V Hausmann1, Michael Seitz, Peter M Villiger, Werner J Pichler.   

Abstract

Biologicals are proteins used as drugs. Biologicals target clearly defined molecular structures, being part of established pathogenetic pathways. Therefore, their focused mode of action seems to render them superior to classic small molecular drugs regarding "off-target" adverse drug reactions (ADR). Nevertheless, the increasing use of biologicals for the treatment of different diseases has revealed partially unexpected adverse reactions. The often direct interaction of a biological with the immune system provides a clue to most side effects, which have consequently been subclassified, based on pathogenetic principles, into 5 subtypes named alpha, beta, gamma, delta, and epsilon, reflecting overstimulation (high cytokine values, type alpha), hypersensitivity (type beta), immune deviation (including immunodeficiency, type gamma), cross-reactivity (type delta), and nonimmune mediated side effects (type epsilon). This article presents typical clinical manifestations of these subtypes of ADR to biologicals, proposes general rules for treating them, and provides a scheme for a thorough allergological workup. This approach should help in future handling of these often very efficient drugs. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609863     DOI: 10.1016/j.mcna.2010.03.001

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  10 in total

1.  New FDA draft guidance on immunogenicity.

Authors:  Ashwin Parenky; Heather Myler; Lakshmi Amaravadi; Karoline Bechtold-Peters; Amy Rosenberg; Susan Kirshner; Valerie Quarmby
Journal:  AAPS J       Date:  2014-03-29       Impact factor: 4.009

Review 2.  [Acute hypersensitivity reactions associated with monoclonal antibodies for targeted therapy].

Authors:  B Sachs; H F Merk
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

Review 3.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 4.  Hypersensitivity Reactions to Biologicals: from Bench to Bedside.

Authors:  Aysegul Akarsu; Ozge Soyer; Bulent Enis Sekerel
Journal:  Curr Treat Options Allergy       Date:  2020-01-18

5.  First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils.

Authors:  Felix Weber; Daniel Breustedt; Sonja Schlicht; Claas A Meyer; Jens Niewoehner; Martin Ebeling; Per-Ola Freskgard; Peter Bruenker; Thomas Singer; Michael Reth; Antonio Iglesias
Journal:  Pharm Res       Date:  2018-06-27       Impact factor: 4.200

6.  Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting.

Authors:  Mayara Costa de Camargo; Bruna Cipriano Almeida Barros; Izabela Fulone; Marcus Tolentino Silva; Miriam Sanches do Nascimento Silveira; Iara Alves de Camargo; Silvio Barberato-Filho; Fernando de Sá Del Fiol; Luciane Cruz Lopes
Journal:  Front Pharmacol       Date:  2019-09-11       Impact factor: 5.810

Review 7.  Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors:  Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal:  Exp Ther Med       Date:  2021-07-03       Impact factor: 2.447

8.  Immunologic evaluation of drug allergy.

Authors:  Enrique Gómez; Maria Jose Torres; Cristobalina Mayorga; Miguel Blanca
Journal:  Allergy Asthma Immunol Res       Date:  2012-05-30       Impact factor: 5.764

9.  Biological drugs for the treatment of psoriasis in a public health system.

Authors:  Luciane Cruz Lopes; Miriam Sanches do Nascimento Silveira; Iara Alves de Camargo; Silvio Barberato-Filho; Fernando de Sá Del Fiol; Claudia Garcia Serpa Osorio-de-Castro
Journal:  Rev Saude Publica       Date:  2014-08       Impact factor: 2.106

Review 10.  Drug allergy.

Authors:  Richard Warrington; Fanny Silviu-Dan; Tiffany Wong
Journal:  Allergy Asthma Clin Immunol       Date:  2018-09-12       Impact factor: 3.406

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.